Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on July 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA acceptance of encaleret NDA for ADH1 advances BridgeBio’s lead regulatory program.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA acceptance of encaleret NDA for ADH1 advances BridgeBio’s lead regulatory program
- Application acceptance initiates FDA review, creating a potential future commercialization catalyst
- Exhibit 99.1 contains the substantive regulatory timeline and program details
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted encaleret’s ADH1 NDA, advancing BridgeBio toward potential first approved therapy for this genetic disorder
- PDUFA target action date May 8, 2027; no FDA advisory committee currently planned
- Phase 3 CALIBRATE met all prespecified primary and key secondary endpoints, supporting regulatory approval prospects
- Over 2,100 U.S. individuals diagnosed with autosomal dominant hypocalcemia since October 2023, indicating a growing addressable market
- Pediatric Phase 2/3 enrollment underway, with Phase 3 chronic hypoparathyroidism study planned to expand encaleret’s commercial potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.